Clinical Trial Search

Primary: Best Overall Response Rate — 33 percentage of participants

Primary: To Evaluate the Efficacy of Combining Everolimus and Bevacizumab in Patients With Advanced RCC of Non-clear Cell Histology — 78 percent of participants

Primary: Progression Free Survival — 9.6 months

Primary: 4-month Progression-Free Survival Rate — 65 percentage of participants — p=0.081

Primary: Observed Response Rate — 0; 11 percentage of patients responding

Primary: Progression Free Survival (PFS) — 5.6; 9.0; 2.8; 3.0 months — p=0.019

Primary: Response Rate — 1; 9.4; 12.6; 76.8 Percentage of participants

Primary: Progression Free Survival (PFS) of Carfilzomib Therapy in Participants With Refractory Or Intolerant to Prior Therapy — 1.8 Months

Primary: Maximum Tolerated Dose (MTD) of BAY 43-9006 (Sorafenib)in Combination With Bevacizumab (Phase I) — 200 mg

Primary: Cohort A: Objective Response Rate (ORR) Assessed by Independent Central Review — 40.5 percentage of participants

Primary: PFS (Progression-Free Survival) — 27.71 Weeks

Primary: Progression-free Survival (PFS) — 2.5 months

Primary: Anti-tumor Activity as Measured by Median Progression Free Survival Time — 5.6; 8.3 Months — p=0.157

Primary: Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease…

Primary: Number of Participants With Response to Treatment — 0; 3; 29; 23 participants

Primary: Progression Free Survival (PFS) — 8.2; 5.6 Months — p=0.012

Primary: Number of Patients With Ani-tumor Activity After Taking OSI-774. — 7 participants

Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 4; 10; 3; 13 participants

Primary: Progression-Free Survival (PFS) — 3.8; 3.6; 3.1 months — p==0.388

Primary: Dose-limiting Toxicity (DLT) (Phase I) — 1; 1 participants

Primary: Progression-free Survival at 3 Months — 2.9 months

Primary: Progression-free Survival (PFS) - All Participants — 7.4 months

Primary: Progression-free Survival — 8.3 months

Primary: Progression-free Survival (PFS) — 7.5; 7.6; 9.2; 7.4 Months — p=0.89

Primary: Phase I: Maximum Tolerated Dose of BNC105P in Combination With Everolimus. — 16 mg/m^2

Primary: Response Rate by Solid Tumor Response Criteria (RECIST) — 16 Percentage of Participants

Primary: Proportion of Patients With Response — 0.18; 0.11 proportion of participants

Primary: Proportion of Patients Alive and Progression-free at 8 Weeks — 0.70; 0.52 proportion of participants

Primary: Progression Free Survival (PFS) — 1.91; 3.81 months — p=0.07905

Primary: Percentage of Participants Who Achieved a Point in Time Objective Response (Either Complete or Partial Response [CR or PR]) Prior to Surgery — 2; 0 Participants